Business Description
Inhibrx Inc
NAICS : 325412
SIC : 2834
ISIN : US45720L1070
Description
Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.13 | |||||
| Equity-to-Asset | 0.06 | |||||
| Debt-to-Equity | 13.74 | |||||
| Debt-to-EBITDA | -1.46 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -0.54 | |||||
| Beneish M-Score | -2.51 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -44.5 | |||||
| 3-Year EBITDA Growth Rate | -28.2 | |||||
| 3-Year EPS without NRI Growth Rate | -29.4 | |||||
| 3-Year FCF Growth Rate | -34.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.29 | |||||
| 9-Day RSI | 51.49 | |||||
| 14-Day RSI | 53.43 | |||||
| 6-1 Month Momentum % | -34.22 | |||||
| 12-1 Month Momentum % | 55.01 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.47 | |||||
| Quick Ratio | 7.47 | |||||
| Cash Ratio | 7.18 | |||||
| Days Sales Outstanding | 80.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.8 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -11239.53 | |||||
| Net Margin % | -12725.63 | |||||
| ROE % | -1344.67 | |||||
| ROA % | -76.56 | |||||
| ROIC % | -948.52 | |||||
| ROC (Joel Greenblatt) % | -1832.45 | |||||
| ROCE % | -77.08 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 779.35 | |||||
| PB Ratio | 69.63 | |||||
| Price-to-Tangible-Book | 69.03 | |||||
| EV-to-EBIT | -7.14 | |||||
| EV-to-Forward-EBIT | -6.46 | |||||
| EV-to-EBITDA | -7.2 | |||||
| EV-to-Forward-EBITDA | -6.49 | |||||
| EV-to-Revenue | 802.62 | |||||
| EV-to-Forward-Revenue | 53.15 | |||||
| EV-to-FCF | -7.97 | |||||
| Price-to-Net-Current-Asset-Value | 201.33 | |||||
| Earnings Yield (Greenblatt) % | -14.01 |
Balance Sheet Breakdown
Cashflow Statement Breakdown
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:INBX
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Inhibrx Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.28 | ||
| EPS (TTM) ($) | -3.94 | ||
| Beta | 0 | ||
| Volatility % | 105.22 | ||
| 14-Day RSI | 53.43 | ||
| 14-Day ATR ($) | 1.711315 | ||
| 20-Day SMA ($) | 24.9785 | ||
| 12-1 Month Momentum % | 55.01 | ||
| 52-Week Range ($) | 7.67 - 34.72 | ||
| Shares Outstanding (Mil) | 43.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Inhibrx Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Inhibrx Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Inhibrx Inc Frequently Asked Questions
What is Inhibrx Inc(INBX)'s stock price today?
The current price of INBX is $24.16. The 52 week high of INBX is $34.72 and 52 week low is $7.67.
When is next earnings date of Inhibrx Inc(INBX)?
The next earnings date of Inhibrx Inc(INBX) is 2023-08-08 Est..
Does Inhibrx Inc(INBX) pay dividends? If so, how much?
Inhibrx Inc(INBX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
